Drug Trial Radar · NCT04798989
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Nov 2, 2021
Primary completion
Nov 28, 2022
Study completion Nov 28, 2022
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.
Conditions
- Alzheimer's Disease With Vascular Pathology
Interventions
CY6463Drug
CY6463 Oral Tablet
PlaceboDrug
Placebo Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-upTime frame: From first dose of study treatment through ~14 (±4) days after the final dose
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Clinical Endpoints
Scottsdale, Arizona
Optimus U Corp
Miami, Florida
Hawaii Pacific Neurosciences, LLC
Honolulu, Hawaii
University of Kentucky
Lexington, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.